Exclusive | Biocon Biologics Q4: Serum Will Double Investment To $300 Mn

Biocon Biologics Ltd.—reported growth of 114% at Rs 2,102 crore, accounting for 50% of the revenue. “As we look ahead, we will be integrating the acquired business (Viatris’ global biosimilars) in a phased manner with over 70 emerging markets transitioning to Biocon Biologics shortly, followed by the U.S. and EU thereafter. FY24 will also see several important new launches, a key driver of growth", said Shreehas Tambe, Chief Executive Officer and Managing Director at Biocon Biologics in an exclusive conversation with Sakshi Batra on the Q4 earnings.